Good
Mostly Aligned
Patient Risk:
Low
Summary
Mostly aligns with the provided FDA label excerpts regarding IL-17A mechanism and avoidance of live vaccines during COSENTYX treatment. Several claims about vaccine timing (4–6 weeks/4 weeks) and vaccine biology (weakened/mild form; stimulates antibodies) are not supported by the supplied label text and include unsupported specifics.
Category Scores
Accurate Statements
Cosentyx works by blocking interleukin-17A (IL-17A).
12.1 Mechanism of Action: binds IL-17A and inhibits its interaction with IL-17 receptor.
COSENTYX may alter a patient's immune response to live vaccines.
5.7 Immunizations: 'COSENTYX may alter a patient's immune response to live vaccines.'
Avoid use of live vaccines in patients treated with COSENTYX.
5.7 Immunizations: 'Avoid use of live vaccines in patients treated with COSENTYX'.
Patients receiving secukinumab should avoid live vaccines for at least 4 weeks after the last dose.
It is not recommended to get a live vaccine while taking Cosentyx, as it may impair the immune response.
5.7 Immunizations and 17 Immunization: 'vaccination with live vaccines is not recommended during COSENTYX treatment.'
Unsupported Statements
Cosentyx (secukinumab) is a biologic medication used to treat autoimmune diseases including psoriasis, psoriatic arthritis, and ankylosing spondylitis.
The provided excerpts do not contain INDICATIONS AND USAGE content or any assessable indication statement.
Live vaccines contain a weakened or mild form of the virus or bacteria that causes the disease.
No definition of live vaccines is provided in the supplied label excerpts (12.1, 5.7, 17).
Live vaccines stimulate the body's immune system to produce antibodies and immune cells that can fight off the infection.
No immunologic mechanism of live vaccines is described in the supplied label excerpts.
The primary concern with taking live vaccines after Cosentyx is the potential for a weakened immune response.
Label excerpt supports altered immune response and avoidance, but the supplied text does not state 'primary concern' or 'weakened immune response' phrasing.
The American Academy of Dermatology recommends waiting at least 4 to 6 weeks after the last dose of Cosentyx before receiving live vaccines.
The supplied label excerpts do not reference AAD recommendations or any timing interval.
The Centers for Disease Control and Prevention suggests waiting at least 4 weeks after the last dose of Cosentyx before receiving live vaccines.
The supplied label excerpts do not reference CDC recommendations or any timing interval.
Patients receiving secukinumab should avoid live vaccines for at least 4 weeks after the last dose.
The supplied label excerpts state to avoid live vaccines during COSENTYX treatment, but they do not provide a post-dose waiting period (e.g., 4 weeks).
The waiting period for live vaccines after taking Cosentyx is not well established.
No statement about 'waiting period not well established' is included in the supplied label excerpts.
Cosentyx can impair the immune response to live vaccines.
The label states COSENTYX 'may alter' immune response to live vaccines, but 'impair' is not the wording used in the supplied excerpts.
The potential risks of getting a live vaccine after Cosentyx include a weakened immune response.
The supplied label excerpts do not specify 'weakened immune response' as the stated risk wording.
Contradictions
Low
AI Statement
Patients receiving secukinumab should avoid live vaccines for at least 4 weeks after the last dose.
Label Reference
5.7 Immunizations and 17 Immunization (supplied excerpts): avoidance during COSENTYX treatment; no label-provided minimum 4-week post-dose interval shown in the supplied text.
Important Omissions
Any label-supported duration/timing interval for live vaccines relative to the last dose (e.g., exact '4 weeks' or '4–6 weeks').
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The core safety-relevant message in the label excerpts is to avoid live vaccines during COSENTYX treatment and note potential alteration of immune response. The main potential issue is unsupported specific waiting-period timing (e.g., 4 weeks/4–6 weeks) not found in the supplied label text.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
Unsupported specific timing recommendations (4–6 weeks/4 weeks) and vaccine definition/mechanism details not contained in the provided label excerpts.
Suggested Improvement
Restrict claims to label-supported statements: COSENTYX may alter immune response to live vaccines; avoid use of live vaccines in patients treated with COSENTYX; live vaccines are not recommended during COSENTYX treatment. Do not add specific waiting intervals or general live-vaccine biology unless present in the label.